

Brilliant Violet 510™ anti-mouse CD45 Antibody

Catalog# / Size	103137 / 125 µL 103138 / 50 µg
Clone	30-F11
Regulatory Status	RUO
Other Names	T200, Ly-5, LCA
Isotype	Rat IgG2b, κ
Description	CD45 is a 180-240 kD glycoprotein also known as the leukocyte common antigen (LCA), T200, or Ly-5. It is a member of the protein tyrosine phosphatase (PTP) family, expressed on all hematopoietic cells except mature erythrocytes and platelets. There are different isoforms of CD45 that arise from variable splicing of exons 4, 5, and 6, which encode A, B, and C determinants, respectively. CD45 plays a key role in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation state of the cell as well as cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	Mouse thymus or spleen
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation	The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 510™ under optimal conditions.
Concentration	µg sizes: 0.2 mg/mL µL sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	<p>Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.</p> <p>Brilliant Violet 510™ excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 510™ is a trademark of Sirigen Group Ltd.</p> <p>Learn more about Brilliant Violet™.</p> <p>This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.</p>
Excitation Laser	Violet Laser (405 nm)

Application Notes

Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45.

Additional reported applications (for relevant formats) include: immunoprecipitation³, complement-dependent cytotoxicity^{1,5}, immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections)^{4,6}, Western blotting⁷, and spatial biology (IBEX)^{10,11}. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/μg, Azide-Free, 0.2 μm filtered) is recommended for functional assays (Cat. No. 103163 and 103164).

Application References

(PubMed link indicates BioLegend citation)

1. Podd BS, *et al.* 2006. *J. Immunol.* 176:6532. (FC, CMCD) [PubMed](#)
2. Haynes NM, *et al.* 2007. *J. Immunol.* 179:5099. (FC)
3. Ledbetter JA, *et al.* 1979. *Immunol. Rev.* 47:63. (IP)
4. Simon DI, *et al.* 2000. *J. Clin. Invest.* 105:293. (IHC)
5. Seaman WE. 1983. *J. Immunol.* 130:1713. (CMCD)
6. Cornet A, *et al.* 2001. *P. Natl. Acad. Sci. USA* 98:13306. (IHC)
7. Tsuboi S and Fukuda M. 1998. *J. Biol. Chem.* 273:30680. (WB) [PubMed](#)
8. Liu F, *et al.* 2012. *Blood.* 119:3295. [PubMed](#)
9. Pelletier AN, *et al.* 2012. *J. Immunol.* 188:5561. [PubMed](#)
10. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
11. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

Product Citations

1. Liu Y, *et al.* 2021. *Cell Metabolism.* 33(6):1221-1233.e11. [PubMed](#)
2. Petrova T, *et al.* 2020. *Sci Rep.* 10:3479. [PubMed](#)
3. Rosina M, *et al.* 2022. *Cell Metab.* 34:533. [PubMed](#)
4. Leslie J, *et al.* 2021. *Sci Rep.* 11:1415. [PubMed](#)
5. Mackel JJ, *et al.* 2022. *Front Cell Infect Microbiol.* 12:974175. [PubMed](#)
6. Cornax I, *et al.* 2021. *Microorganisms.* 9:00. [PubMed](#)
7. Benitez AA, *et al.* 2020. *Commun Biol.* 0.371527778. [PubMed](#)
8. Gawish R, *et al.* 2022. *Elife.* 11:.. [PubMed](#)
9. Li X, *et al.* 2022. *Nat Commun.* 13:2794. [PubMed](#)
10. Boal-Carvalho I, *et al.* 2020. *EMBO Rep.* 21:e50421. [PubMed](#)
11. Afolabi LO, *et al.* 2021. *Front Immunol.* 12:701671. [PubMed](#)
12. Zhang Y, *et al.* 2020. *Oncol Lett.* 1.053472222. [PubMed](#)
13. Li JY, *et al.* 2020. *J Clin Invest.* 130:1767. [PubMed](#)
14. Dong L, *et al.* 2021. *Cancer Cell.* . [PubMed](#)
15. Pan XX, *et al.* 2021. *Front Cell Dev Biol.* 637424:9. [PubMed](#)
16. Scott CL *et al.* 2018. *Immunity.* 49(2):312-325 . [PubMed](#)
17. Lancaster JN, *et al.* 2019. *Nat Commun.* 10:2220. [PubMed](#)
18. Zhang K, *et al.* 2018. *PLoS Pathog.* 14:e1006925. [PubMed](#)
19. Li Y, *et al.* 2021. *Basic Res Cardiol.* 116:30. [PubMed](#)
20. Poli V, *et al.* 2021. *iScience.* 24:103256. [PubMed](#)
21. Matsumoto R, *et al.* 2021. *Front Pharmacol.* 12:715752. [PubMed](#)
22. Alam J, *et al.* 2022. *Mucosal Immunol.* 15:620. [PubMed](#)
23. Devalaraja S, *et al.* 2020. *Cell.* 1098:180. [PubMed](#)
24. Upadhyaya P, *et al.* 2021. *J Immunother Cancer.* 9:00. [PubMed](#)
25. Hiraishi Y, *et al.* 2018. *Sci Rep.* 8:18052. [PubMed](#)
26. Wang L, *et al.* 2022. *Cancer Res Commun.* 2:518. [PubMed](#)
27. Starkl P, *et al.* 2020. *Immunity.* 53(4):793-804.e9. [PubMed](#)
28. Wang Y, *et al.* 2021. *Cancer Cell.* .: [PubMed](#)
29. Antonia O Cuff *et al.* 2017. *Wellcome open research.* 2:39 . [PubMed](#)
30. Di Gioia M, *et al.* 2020. *Nat Immunol.* 21:42. [PubMed](#)
31. Somerville TD, *et al.* 2020. *eLife.* 9:e53381.. [PubMed](#)
32. Lees JG, *et al.* 2020. *PLoS One.* 15:e0238164. [PubMed](#)
33. Sun Q, *et al.* 2022. *Cell Death Dis.* 13:724. [PubMed](#)
34. Yoshihara E, *et al.* 2020. *Nature.* 606:586. [PubMed](#)
35. Huang X, *et al.* 2020. *Cell Host Microbe.* 29(2):210-221.e6. [PubMed](#)
36. LaMarche NM, *et al.* 2020. *Cell Metabolism.* 32(2):243-258.e6. [PubMed](#)
37. Cuff AO, *et al.* 2020. *Frontiers in Immunology.* 1.930555556. [PubMed](#)
38. Thanabalasuriar A *et al.* 2019. *Cell Host Microbe.* 25(4):526-536 . [PubMed](#)
39. Yu M, *et al.* 2021. *J Clin Invest.* 131:.. [PubMed](#)
40. Ma M, *et al.* 2021. *Front Immunol.* 12:718779. [PubMed](#)
41. Xu Y, *et al.* 2021. *Stem Cell Res Ther.* 12:112. [PubMed](#)
42. Dikiy S, *et al.* 2021. *Immunity.* 54(5):931-946.e11. [PubMed](#)
43. Devalaraja S, *et al.* 2020. *STAR Protoc.* 1:100188. [PubMed](#)
44. Pandey V, *et al.* 2021. *eLife.* 0.4166666666666667. [PubMed](#)
45. Taguchi K, *et al.* 2015. *J Urol.* . [PubMed](#)
46. Duc D *et al.* 2019. *Cell Rep.* 29(2):378-390 . [PubMed](#)
47. Linde N, *et al.* 2018. *Nat Commun.* 9:21. [PubMed](#)
48. Wang H, *et al.* 2021. *Malar J.* 20:249. [PubMed](#)
49. Taguchi K, *et al.* 2014. *J Am Soc Nephrol.* 25:1680. [PubMed](#)
50. Tyagi AM, *et al.* 2021. *eLife.* 10:00. [PubMed](#)
51. Neupane AS, *et al.* 2020. *Cell.* 183(1):110-125.e11. [PubMed](#)
52. Thiriot A *et al.* 2017. *BMC biology.* 15(1):45 . [PubMed](#)
53. Knolle MD *et al.* 2018. *Frontiers in immunology.* 1.925 . [PubMed](#)
54. Linehan JL *et al.* 2018. *Cell.* 172(4):784-796 . [PubMed](#)
55. Kooreman NG *et al.* 2018. *Cell stem cell.* 22(4):501-513 . [PubMed](#)
56. Bonnardel J, *et al.* 2019. *Immunity.* 51:638. [PubMed](#)
57. Leylek R, *et al.* 2019. *Cell Rep.* 29:3736. [PubMed](#)

58. Yang P, *et al.* 2022. Nat Commun. 13:5782. [PubMed](#)
59. Weaver JD, *et al.* 2022. Oncoimmunology. 11:2141007. [PubMed](#)
60. Brigas HC, *et al.* 2021. Cell Reports. 36(9):109574. [PubMed](#)
61. Dang MT, *et al.* 2021. Cell Reports. 34(13):108917. [PubMed](#)
62. Nagai M, *et al.* 2020. Cell. 178(5):1072-1087.e14.. [PubMed](#)
63. Silver J, *et al.* 2020. Methods Mol Biol. 2121:115. [PubMed](#)
64. Zhang Y, *et al.* 2021. J Immunol Res. 2021:5599439. [PubMed](#)
65. Reinfeld BI, *et al.* 2021. Nature. 593:282. [PubMed](#)
66. Panea C, *et al.* 2021. Commun Biol. 4:913. [PubMed](#)
67. Lima-Junior DS, *et al.* 2021. Cell. . [PubMed](#)
68. Jacobson A *et al.* 2018. Cell host & microbe. 24(2):296-307 . [PubMed](#)
69. Casulli J, *et al.* 2019. Nat Commun. 10:2121. [PubMed](#)
70. Cheng Y, *et al.* 2019. Clin Cancer Res. 25:2621. [PubMed](#)
71. Alam J, *et al.* 2021. Front Immunol. 12:701415. [PubMed](#)
72. Jorapur A, *et al.* 2022. PLoS Pathog. 18:e1010200. [PubMed](#)
73. Kalavska K, *et al.* 2021. Int J Mol Sci. 22:. [PubMed](#)
74. Frenis K, *et al.* 2021. Basic Res Cardiol. 31:116. [PubMed](#)
75. Devi IMW, *et al.* 2021. Cell Reports Medicine. 2(5):100289. [PubMed](#)
76. Walsh SM, *et al.* 2021. eLife. 10:00. [PubMed](#)
77. LM S, *et al.* 2016. Cell Rep. 16(12): 3286-96. [PubMed](#)
78. Guilliams M, *et al.* 2022. Cell. 185:379. [PubMed](#)
79. Stacy A, *et al.* 2021. Cell. 184(3):615-627.e17. [PubMed](#)
80. Alam Z, *et al.* 2020. Cell Rep. 107825:31. [PubMed](#)
81. Xiao Y, *et al.* 2018. Int Immunol. 30:457. [PubMed](#)
82. Ayari A, *et al.* 2020. Commun Biol. 3:237. [PubMed](#)
83. Dang MT, *et al.* 2021. STAR Protoc. 2:100957. [PubMed](#)
84. Espinal A, *et al.* 2022. Int J Mol Sci. 23: [PubMed](#)
85. Louka E, *et al.* 2021. Journal of Experimental Medicine. 218(2):. [PubMed](#)
86. Holm J, *et al.* 2015. PLoS One. 10:125495. [PubMed](#)
87. Jordan S, *et al.* 2020. Cell. 178(5):1102-1114.e17.. [PubMed](#)
88. Gladow N, *et al.* 2020. PLoS One. 15:e0227734. [PubMed](#)
89. Kalavska K, *et al.* 2022. Front Oncol. 12:858797. [PubMed](#)
90. Zhang XW, *et al.* 2021. Oncoimmunology. 10:1920739. [PubMed](#)
91. Zeis P, *et al.* 2020. Immunity. 53:775. [PubMed](#)
92. Calderon B, *et al.* 2015. J Exp Med. 212: 1497-1512. [PubMed](#)
93. Tian Y, *et al.* 2020. JCI Insight. 5:00. [PubMed](#)
94. Jiang L, *et al.* 2020. Cell. 183(5):1219-1233.e18. [PubMed](#)
95. Hoffmann J, *et al.* 2021. Nat Commun. 12:3964. [PubMed](#)
96. Carlson PM, *et al.* 2021. J Immunol. 207:720. [PubMed](#)
97. Seki N, *et al.* 2022. iScience. 25:104838. [PubMed](#)
98. Chen H, *et al.* 2022. Mol Ther Methods Clin Dev. 27:431. [PubMed](#)
99. Montalban-Arques A, *et al.* 2021. Cell Host Microbe. . [PubMed](#)
100. Asadi Shahmirzadi A, *et al.* 2020. Cell Metabolism. 32(3):447-456.e6. [PubMed](#)
101. Mairhofer D, *et al.* 2015. J Invest Dermatol. 135: 2785-93. [PubMed](#)
102. Silva DA, *et al.* 2019. Nature. 565:186. [PubMed](#)
103. Xu JL, *et al.* 2022. Front Pharmacol. 13:911663. [PubMed](#)
104. Hering L, *et al.* 2020. Front Immunol. 1.747222222. [PubMed](#)
105. Halim TYF *et al.* 2018. Immunity. 48(6):1195-1207 . [PubMed](#)
106. Yoshida H, *et al.* 2019. Cell. 176:897. [PubMed](#)
107. Sugita Y, *et al.* 2021. Oncol Rep. 45:. [PubMed](#)
108. Zamarin D, *et al.* 2020. Clin Cancer Res. 26:4531. [PubMed](#)
109. Domanska D, *et al.* 2022. J Exp Med. 219:. [PubMed](#)
110. Liu J, *et al.* 2022. Nat Commun. 13:4308. [PubMed](#)
111. Aulova KS, *et al.* 2022. Molecules. 27:. [PubMed](#)
112. Xia L, *et al.* 2021. Cell Chemical Biology. 28(5):610-624.e5. [PubMed](#)
113. Wan X, Thomas J, Unanue E 2016. J Exp Med. 213: 967 - 978. [PubMed](#)
114. Ramanan D, *et al.* 2020. Cell. 181(6):1276-1290. [PubMed](#)
115. Li X, *et al.* 2022. Oncoimmunology. 11:2118210. [PubMed](#)
116. Smith LK, *et al.* 2021. Elife. 10:. [PubMed](#)
117. Catrysse L, *et al.* 2021. Cell Rep. 36:109748. [PubMed](#)
118. Wang X, *et al.* 2021. Theranostics. 11:209. [PubMed](#)
119. Tran S, *et al.* 2020. Immunity. 53(3):627-640.e5. [PubMed](#)
120. Wang X, *et al.* 2021. Immunity. 54(6):1123-1136.e8. [PubMed](#)
121. Wunderlich CM, *et al.* 2018. Nat Commun. 9:1646. [PubMed](#)
122. Li Z *et al.* 2018. Immunity. 49(4):640-653 . [PubMed](#)
123. Tripathi A, *et al.* 2021. Mol Psychiatry. 26:3043. [PubMed](#)
124. Jiang M, *et al.* 2021. Front Pharmacol. 12:657486. [PubMed](#)
125. Dourcy M, *et al.* 2020. Mucosal Immunol. 13:799. [PubMed](#)
126. Sfakianos JP, *et al.* 2020. Nat Commun. 2.222222222. [PubMed](#)
127. Deniset JF *et al.* 2019. Immunity. 51(1):131-140 . [PubMed](#)
128. Weinstock A, *et al.* 2019. Immunometabolism. 1. [PubMed](#)
129. Figueiredo CA, *et al.* 2022. J Neuroinflammation. 19:17. [PubMed](#)
130. Li X, *et al.* 2021. Front Cell Dev Biol. 9:647713. [PubMed](#)

RRID

AB_2561392 (BioLegend Cat. No. 103137)

AB_2563061 (BioLegend Cat. No. 103138)

Antigen Details

Structure	Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution	All hematopoietic cells except mature erythrocytes and platelets
Function	Phosphatase, T and B cell activation
Ligand/Receptor	Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1
Cell Type	B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs
Biology Area	Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
Molecular Family	CD Molecules
Antigen References	<ol style="list-style-type: none">1. Barclay A, <i>et al.</i> 1997. The Leukocyte Antigen FactsBook Academic Press.2. Trowbridge IS, <i>et al.</i> 1993. <i>Annu. Rev. Immunol.</i> 12:85.3. Kishihara K, <i>et al.</i> 1993. <i>Cell</i> 74:143.4. Pulido R, <i>et al.</i> 1988. <i>J. Immunol.</i> 140:3851.
Gene ID	19264


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

APC anti-mouse CD45, Biotin anti-mouse CD45, FITC anti-mouse CD45, PE anti-mouse CD45, PE/Cyanine5 anti-mouse CD45, Purified anti-mouse CD45, PE/Cyanine7 anti-mouse CD45, APC/Cyanine7 anti-mouse CD45, Alexa Fluor® 488 anti-mouse CD45, Alexa Fluor® 647 anti-mouse CD45, Pacific Blue™ anti-mouse CD45, Alexa Fluor® 700 anti-mouse CD45, PerCP/Cyanine5.5 anti-mouse CD45, PerCP anti-mouse CD45, Alexa Fluor® 594 anti-mouse CD45, Brilliant Violet 421™ anti-mouse CD45, Brilliant Violet 570™ anti-mouse CD45, Brilliant Violet 510™ anti-mouse CD45, Brilliant Violet 605™ anti-mouse CD45, Purified anti-mouse CD45 (Maxpar® Ready), PE/Dazzle™ 594 anti-mouse CD45, Brilliant Violet 711™ anti-mouse CD45, Brilliant Violet 785™ anti-mouse CD45, Brilliant Violet 650™ anti-mouse CD45, APC/Fire™ 750 anti-mouse CD45, Brilliant Violet 750™ anti-mouse CD45, TotalSeq™-A0096 anti-mouse CD45, TotalSeq™-B0096 anti-mouse CD45, Ultra-LEAF™ Purified anti-mouse CD45, Spark Blue™ 550 anti-mouse CD45, Spark NIR™ 685 anti-mouse CD45, TotalSeq™-C0096 anti-mouse CD45, Spark YG™ 570 anti-mouse CD45, PE/Fire™ 640 anti-mouse CD45, APC/Fire™ 810 anti-mouse CD45, PE/Fire™ 700 anti-mouse CD45, Spark Violet™ 538 anti-mouse CD45, Spark YG™ 593 anti-mouse CD45, Spark Blue™ 574 anti-mouse CD45 Antibody

Product Data



C57BL/6 mouse splenocytes were stained with CD45 (clone 30-F11) Brilliant Violet 510™.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587